Courtesy of Benzinga.
Actavis plc (NYSE: ACT) is acquiring Allergan, Inc. (NYSE: AGN) for $66 billion or $129 per share, thus avoiding being acquired by Valeant and Pershing Square, according to CNBC’s David Faber.
Actavis to buy Allergan for $129 in cash and .3683 ACT share. Deal worth $219 at open of trading.
— DAVID FABER (@davidfaber) November 17, 2014
Valeant has said it cannot justify paying that price. This likely ends the ongoing sage between Bill Ackman of Pershing Square and Allergan.
Shares of Allergan were trading higher by 7 percent at $212.70, while shares of Actavis were higher by 3.7 percent at $252.80.